Regeneron Pharmaceuticals stock falls 1.66% and underperforms competitors

6 articles · Updated · MarketWatch · May 7

Shares closed at $709.10 on Thursday as the S&P 500 fell 0.38% to 7,337.11 and the Dow dropped 0.63% to 49,596.97.
Regeneron ended 13.64% below its 52-week high of $821.11 reached on 9 January, while Amgen, Moderna and Gilead posted smaller declines.
Trading volume reached 773,878 shares, above the 50-day average of 675,115, during a broadly weak session for US equities.

Regeneron's stock fell despite record earnings. Is its blockbuster drug era truly over?

Regeneron is giving away its new gene therapy. What is the hidden cost of this free drug strategy?